SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

UncategorizedOctober 17, 2026

Community indicators flagged high lung cancer incidence areas in California better than smoking alone

Area-level data on smoking, pollution and population characteristics identified Californian communities with high lung cancer incidence more accurately than smoking prevalence alone, according to an analysis by Gianni Pucillo and colleagues published in Cancer Epidemiology, Biomarkers & Prevention.
Share

In brief

  • An ecological analysis of 542 Medical Service Study Areas in California related age-adjusted lung cancer incidence for 2015–2019 to 27 community-level indicators of pollution, population characteristics and adult smoking prevalence.
  • A support vector machine trained on 15 of those indicators separated high-incidence from low-incidence areas with a cross-validation AUC of 0.891, against 0.685 for a model using smoking prevalence alone.
  • Smoking, linguistic isolation, neighbourhood socioeconomic status, unemployment and housing burden made the largest contributions to the classification.
  • In regression, a higher neighbourhood socioeconomic status quintile (standardised β = −0.57) and a higher Hispanic population proportion (β = −0.51) were the strongest predictors of lower incidence.
  • Discrimination was better for White-specific incidence (AUC 0.926) than for Hispanic-specific incidence (AUC 0.744), and the authors state that no causal interpretation is intended.

Study at a glance

  • Design: Ecological analysis of area-level data
  • Units: 542 Medical Service Study Areas in California
  • Outcome: Age-adjusted lung cancer incidence rate, 2015–2019
  • Indicators: 27 measures of pollution, population characteristics and adult smoking prevalence
  • Best classifier: Support vector machine (radial basis function kernel) on 15 autoencoder-selected indicators, cross-validation AUC 0.891
  • Comparator: Smoking-only model, AUC 0.685
  • Strongest regression predictors of lower incidence: Neighbourhood socioeconomic status quintile (β = −0.57), Hispanic population proportion (β = −0.51)
  • Subpopulation models: White-specific incidence AUC 0.926, Hispanic-specific incidence AUC 0.744
  • Not reported: The size of the association with Black population proportion, which the abstract does not give

Fifteen community indicators discriminated better than smoking prevalence alone

The investigators matched incidence rates for 2015–2019 in each of the 542 study areas to 27 indicators, used an autoencoder to select 15 of them, and trained classifiers to distinguish areas of high incidence from areas of low incidence.

A support vector machine with a radial basis function kernel performed best, with a cross-validation AUC of 0.891. The model given smoking prevalence alone reached 0.685.

SHapley Additive exPlanations (SHAP) analysis named five indicators as the largest contributors to the classification: smoking, linguistic isolation, neighbourhood socioeconomic status, unemployment and housing burden.

Neighbourhood socioeconomic status gave the largest regression coefficient

Ordinary least squares regression returned a standardised β of −0.57 for neighbourhood socioeconomic status quintile and −0.51 for the proportion of Hispanic residents, each corresponding to lower age-adjusted incidence.

A higher proportion of Black residents was associated with higher incidence.

Weaker discrimination for Hispanic-specific incidence

Stratified by subpopulation, the models reached an AUC of 0.926 for White-specific incidence and 0.744 for Hispanic-specific incidence. The authors write that lower predictive performance in some subpopulations points to data gaps, which they say must be addressed for equitable cancer prevention.

“Community-level smoking, pollution, and population characteristics data improved the identification of regions with elevated lung cancer risk.”Pucillo et al., Cancer Epidemiology, Biomarkers & Prevention (2026)

Concurrent associations in one state, with no causal claim

The authors describe the associations as concurrent rather than aetiological. Because exposure and incidence were both measured for the area as a whole, an area with high incidence and high linguistic isolation does not show that its linguistically isolated residents carry the excess risk.

All 542 areas lie in California, and the abstract describes cross-validation within that dataset only, with no testing in another state or period. The authors propose that community-level indicators could identify areas of elevated lung cancer burden, including many with suppressed registry rates.

Sources

  1. Cancer Epidemiology Biomarkers & Prevention. Machine Learning Identifies Community-Level Factors Associated with Lung Cancer Incidence (2026-10-15). doi.org

Featuring Lung Summit faculty

This study was co-authored by Lung Summit faculty Sandip Patel.

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Tags
Share

       Continue With

Related Topics

Videos
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Nov132026
ILCS 2026

The International Lung Cancer Summit 2026

Learn more about the event

S. PetersA. AddeoM. DasH. HorinouchiT. SequeiraC. LovlyD. PlanchardS. PatelA. CortelliniN. FrostG. MountziosA. Dingemans
Oct252026
ESMO 2026 SYMPOSIUM
SCLC

SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era

Learn more about the event

M. ReckS. PetersG. MountziosN. Reguart
Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC
May 04 2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
ILCS 2025
SCLC

Reshaping Approaches in SCLC with the Latest Advances in LS- and ES-Disease

} 34 min

R. Manochakian
Sep 26 2025
ILCS 2025
Advanced NSCLC

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

A. Curioni-Fontecedro
Sep 26 2025
ILCS 2025
Immunotherapies

The Role of IO Added to Chemoradiation in Unresectable Stage III NSCLC

} 28 min

A. Filippi
Sep 26 2025
ILCS 2025
Immunotherapies

Tailoring IO in Res. NSCLC: Personalized Approaches for Improved Outcomes

} 36 min

P. Forde
Sep 26 2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro
Sep 26 2025
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

A. Passaro
Sep 26 2025
ILCS 2025
ADCs

The ADC Revolution in Lung Cancer: New Targets, New Opportunities

} 27 min

N. Reguart
Sep 26 2025
ILCS 2025
Targeted Therapies

DEBATE: Which Is the Better Choice in EGFR+ Advanced NSCLC?

} 31 min

T. Newsom-DavisX. Le
Sep 26 2025
ILCS 2025
Targeted Therapies

Actionable Genomic Alterations – Including HER2 and MET

} 26 min

S. Saw
Sep 26 2025
ILCS 2025
Targeted Therapies

Targeting EGFR and ALK in NSCLC

} 26 min

T. John
Sep 26 2025
ILCS 2025
Biomarkers

Cutting-Edge Diagnostic Techniques and Emerging Biomarkers

} 24 min

M. Ilié
Sep 26 2025
ILCS 2025
Advanced NSCLC

Open Discussion on Patient Cases

} 22 min

Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard
Jul 10 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCTargeted Therapies

Targeted Therapies in NSCLC

} 1h 30 min

O. GautschiJ. NaidooN. Girard
IO in NSCLC by Solange Peters, Jordi Remon, Patrick Forde
Jun 25 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCImmunotherapies

Immunotherapies in NSCLC

} 1h 47 min

P. FordeJ. RemonS. Peters
SCLC by Solange Peters, Giannis Mountzios, Jacob Sands
Jun 17 2025
VIRTUAL ROUNDTABLE
SCLCImmunotherapies

Small Cell Lung Cancer

} 1h 35 min

G. MountziosJ. SandsS. Peters
Articles
Oct 16 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months

A. CallesJ. RemonA. CortelliniD. PlanchardB. Ricciuti
Oct 16 2026
RESEARCH
Advanced NSCLC

Fixation protocol determined immunocytochemistry performance on lung cancer cytology slides in an IASLC study

L. Bubendorf
Oct 15 2026
NEWS
Resectable NSCLC

A papal diagnosis turns the world’s attention to its most diagnosed cancer

Oct 14 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Durable responders to immunotherapy for NSCLC or melanoma mostly reported good health, but frequent fatigue

N. Girard
Oct 14 2026
RESEARCH
Resectable NSCLC

More lymph nodes examined at segmentectomy tracked with longer survival in early-stage NSCLC

J. Perentes
Oct 08 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Amivantamab, lazertinib and bevacizumab gave a 33% response rate after osimertinib in AMAZE-lung

R. StahelM. PérolA. AddeoS. Peters
Oct 07 2026
RESEARCH
BiomarkersSCLC

IASLC pathologists propose a grade 3 category for lung carcinoids with more than 10 mitoses

P. Hofman
Oct 06 2026
RESEARCH

Four Austrian societies back a national, risk-adapted lung cancer screening programme

M. Hochmair
Oct 06 2026
RESEARCH
Advanced NSCLCImmunotherapies

Two-thirds of patients with PD-L1-high NSCLC received first-line immunotherapy alone in a real-world survey

D. Rodríguez-Abreu
Alfredo Addeo
Oct 05 2026
RESEARCH
Advanced NSCLCTargeted Therapies

A JCO review sets PACC mutations and exon 20 insertions apart from classical EGFR mutations in NSCLC

A. AddeoX. Le
Oct 05 2026
RESEARCH
SCLCImmunotherapies

Second-line therapy in ES-SCLC gave a median OS of 7.1 months in the Austrian LALUCA registry

M. Hochmair
Nikolaj Frost
Oct 04 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

Checkpoint inhibitors were associated with longer survival in NSCLC after allogeneic stem cell transplantation

N. FrostM. ReckA. Cortellini
Oct 04 2026
RESEARCH
SCLCImmunotherapies

Longer OS in Asian than non-Asian patients given atezolizumab plus chemotherapy for extensive-stage SCLC

S. LiuM. ReckC. Rudin
Oct 03 2026
RESEARCH
Advanced NSCLCResectable NSCLCTargeted Therapies

AI-extracted records describe stage I–III NSCLC care at four Spanish hospitals before immunotherapy

A. Calles
Oct 03 2026
RESEARCH
Advanced NSCLCTargeted Therapies

KRAS inhibitors in NSCLC: modest survival gains, inevitable resistance and combinations in early trials

V. Noronha
Oct 02 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Sutetinib produced responses in 71% of patients with uncommon EGFR mutations in a phase IIb trial

X. Le
Oct 02 2026
RESEARCH
Advanced NSCLCBiomarkersImmunotherapies

High tumour mutational burden was associated with more frequent and earlier immune-related adverse events in advanced NSCLC

B. Ricciuti
Oct 01 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Uncommon EGFR exon 19 deletions were associated with shorter PFS on osimertinib in a 111-patient study

H. Horinouchi
Oct 01 2026
RESEARCH
Targeted Therapies

RAS alterations drove resistance in about one in ten oncogene-driven lung cancers progressing on targeted therapy

B. RicciutiJ. RemonD. Planchard
Sep 30 2026
RESEARCH
Advanced NSCLCSCLCADCs

Pulmonary adverse events affected almost a third of lung cancer patients treated with ADCs in a 24-study meta-analysis

C. Rolfo